MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-GJ-20-0010152
Revenue · FY 2025
₹28.24 Cr
▲ 154% YoY
Net loss · FY 2025
₹2.09 Cr
Net margin -7.4%
EBITDA · FY 2025
-₹77.79 Lakh
EBITDA margin -2.8%
Authorised capital
₹10 Cr
Registered with MCA
Paid-up capital
₹3.74 Cr
Issued & subscribed
Open charges
₹8.4 Cr
Satisfied ₹14.96 Cr
Company age
32 yrs
Est. 1994
Employees · EPFO
9
Provident fund records
About Parmax Pharma Limited
Data last updated:
Parmax Pharma Limited is a public limited company based in Hadamtala, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 02 November 1994 and has been in existence for over 32 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24231GJ1994PLC023504. Its GSTIN is 24AADCP9295L1ZS (Gujarat). It is recorded as listed by MCA, but trading in its shares on BSE (540359) has been suspended, so they do not currently trade on a stock exchange.
The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹3.74 Cr. It is led by directors including Umang Alkesh Gosalia (Managing Director) and Ami Shah Rajeshbhai.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No. 20 Survey No. 52 Rajkot – Gondal National Highway No. 27, Hadamtala, Gujarat, India – 360311.
As per the financials filed for FY 2025, the company reported a revenue of ₹28.24 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net loss of ₹2.09 Cr (net margin -7.4%) and EBITDA of -₹77.79 Lakh (EBITDA margin -2.8%). Revenue has grown at a compounded annual rate (CAGR) of 16% over three years and 6% over five years.
The company has about 9 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Parmax Pharma. As per MCA filings, the company has open charges of ₹8.4 Cr and satisfied charges of ₹14.96 Cr on record. Court records list 2 cases involving the company, including 2 filed against it. The company has 7 deals on record (7 market trades); the latest was in August 2026. Its 9 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Asg Biochem Private Limited with revenue of ₹28.92 Cr. The company has 1 MSME Form 1 return on record for the period ending Jan 2019, listing 26 overdue payments to 4 micro and small suppliers.
Parmax Pharma Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-20-0010152). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website parmaxpharma.com.
Company details
CIN L24231GJ1994PLC023504
Registration Number 023504
Incorporation Date 02 November 1994
ROC Ahmedabad
Listing Status Listed - Suspended on BSE (540359)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-GJ-20-0010152
Key People
Umang Alkesh Gosalia Managing Director Ami Shah Rajeshbhai Director Nikhil Sureshchandra Uchat Director Recognitions & Rankings of Parmax Pharma
Contact details
Parmax Pharma Limited's registered office is in Hadamtala, Gujarat. Its website is parmaxpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressPlot No. 20 Survey No. 52 Rajkot – Gondal National Highway No. 27, Hadamtala, Gujarat, India – 360311
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Parmax Pharma Limited, buy the company report.
Comprehensive company report
Parmax Pharma Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Parmax Pharma operates one associated brand: Parmax Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Parmax Pharma Ltd is a pharmaceutical company that manufactures and sells bulk drugs, drugs intermediates, and specialty chemicals, with a focus on leveraging its scientific expertise and strong manufacturing capabilities to drive growth and profitability. | parmaxpharma.com |
Business activity
The main business activity of Parmax Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Parmax Pharma Limited, buy the company report.
Financials of Parmax Pharma Limited
FY 2025 filings availableParmax Pharma Limited reported revenue of ₹28.24 Cr (up 154% YoY) for FY 2025.
Revenue · FY 2025
₹28.24 Cr ▲ 154%
Net loss · FY 2025
₹2.09 Cr margin -7.4%
EBITDA · FY 2025
-₹77.79 Lakh margin -2.8%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 154%
3 years · compounded
▲ 16%
5 years · compounded
▲ 6%
EBITDA CAGR growth
1 year
▲ 77%
3 years · compounded
▼ 32%
5 years · compounded
▼ 19%
Revenue has grown at a compounded annual rate (CAGR) of 6% over five years, including 154% growth in the latest year. EBITDA rose 77% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹77.79 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹2.09 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -2.8% | ||||
| Net Profit Margin | -7.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Parmax Pharma Limited, buy the company report.
Board of directors of Parmax Pharma Limited
Parmax Pharma has 5 current directors and 14 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ami Shah Rajeshbhai | Director | 17 Jun 2018 | 8 Years 4 Months | Current |
| Umang Alkesh Gosalia Also directs: Malwin Pharma Private Limited | Managing Director | 02 Jan 2016 | 10 Years 9 Months | Current |
| Nikhil Sureshchandra Uchat | Director | 25 Apr 2023 | 3 Years 6 Months | Current |
| Pradeep Ramniklal Gosalia Also directs: Malwin Pharma Private Limited | Director | 27 May 2026 | 0 Years 5 Months | Current |
| Salma Badrudin Thobhani | Director | 27 May 2026 | 0 Years 5 Months | Current |
Peer comparison
Parmax Pharma Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Asg Biochem Private Limited | ₹28.92 Cr (FY 2025) | -9.0% | New Delhi, Delhi, India | |||
| Livmore Life Sciences Private Limited | ₹28.89 Cr (FY 2025) | 296.0% | Vadodara, Gujarat, India | |||
| Surya Remedies Private Limited | ₹28.86 Cr (FY 2024) | 9.0% | Ankleshwar, Gujarat, India | |||
| Pranami Drugs Private Limited | ₹28.27 Cr (FY 2025) | 17.0% | Ankleshwar, Gujarat, India | |||
| Parmax Pharma Limitedthis company | ₹28.24 Cr (FY 2025) | -₹2.09 Cr | -7.4% | 154.0% | 9 | Hadamtala, Gujarat, India |
| Aresko Life Sciences Private Limited | ₹27.87 Cr (FY 2025) | 35.0% | New Delhi, Delhi, India | |||
| Progress Life Sciences Private Limited | ₹27.83 Cr (FY 2025) | 1.0% | Navi Mumbai, Maharashtra, India | |||
| Nandu Chemicals Private Limited | ₹27.74 Cr (FY 2025) | 16.0% | Hubli, Karnataka, India | |||
| Enzal Chemicals (India) Limited | ₹27.7 Cr (FY 2025) | 29.0% | Mumbai, Maharashtra, India | |||
| Altra Pharma-Chem Private Limited | ₹27.64 Cr (FY 2024) | -36.0% | Thane, Maharashtra, India |
To see the full peer comparison of Parmax Pharma Limited, buy the company report.
Auditor
Parmax Pharma Limited is audited by B A Shah S R Mehta & Co. for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| B A Shah S R Mehta & Co. | FY 2024 | 128796W |
Shareholding
The shareholding of Parmax Pharma Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Parmax Pharma Limited, buy the company report.
Charges & borrowings
Open charges
₹8.4 Cr
Satisfied charges
₹14.96 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 17 Apr 2025 | 101092470 | Others | ₹8.4 Cr | Open | |
| 31 May 2023 | 100775935 | Others | ₹6.72 Cr | Satisfied | |
| 08 Feb 2019 | 100240259 | Hdfc Bank Limited | ₹1.12 Cr | Satisfied | |
| 16 Oct 2018 | 100215130 | Hdfc Bank Limited | ₹6.85 Cr | Satisfied | |
| 28 Jul 2017 | 100172862 | Hdfc Bank Limited | ₹26.7 Lakh | Satisfied |
To see the full charge records of Parmax Pharma Limited, buy the company report.
Total charge records: 5 View all charges
Deals & funding
Parmax Pharma Limited has 7 deals on record (7 market trades); the latest was in August 2026.
Total deals
7
Market trades
7
Deals on record (5 of 7)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2026 | Market trade | ₹26.2 Lakh | Buyer: an individual |
| Aug 2026 | Market trade | ₹56.1 Lakh | Buyer: an individual Seller: Neo Apex Share Broking Services LLP |
| Jul 2026 | Market trade | ₹97.2 Lakh | Buyer: Neo Apex Share Broking Services LLP , an individual Seller: an individual |
| Jul 2026 | Market trade | ₹1.11 Cr | Buyer: Multiplier Share and Stock Advisors Private Limited , an individual Seller: Multiplier Share and Stock Advisors Private Limited , Neo Apex Share Broking Services LLP , Epitome Trading And Investments |
| Jul 2026 | Market trade | ₹30.8 Lakh | Buyer: Multiplier Share and Stock Advisors Private Limited Seller: an individual |
To see the full deal history of Parmax Pharma Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Parmax Pharma Limited has 2 court cases on record: 2 filed against it. All cases are disposed.
Total cases
2
Filed against the company
2
Disposed
2
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 2 | 2 | 0 |
Cases on record (2 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Ahmedabad, Gujarat | Criminal complaint | Filed against the company by an individual | Disposed |
| District court, Ahmedabad, Gujarat | Criminal complaint | Filed against the company by Registor of Company | Disposed |
To see the full case history of Parmax Pharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Parmax Pharma Limited has 1 MSME Form 1 return on record for the period ending Jan 2019, listing 26 overdue payments to 4 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (4 of 4)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Krishna Scientific Traders | |||
| Steelman Gases Pvt Ltd | |||
| Yash Scientific Industries | |||
| Vaibhav Analytical Services |
To see the full MSME payment records of Parmax Pharma Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Parmax Pharma Limited has a workforce of 9 employees on its EPFO records as of Apr 08, 2024, across 1 active EPFO establishment.
Employee count
9
Active EPFO establishments
1
Employee growth
-64%
GST
Parmax Pharma has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AADCP9295L1ZS | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Parmax Pharma Limited, buy the company report.
Recent activity
Parmax Pharma Limited has 27 board changes on record since 1994: 16 appointments and 11 cessations. The latest: Pradeep Ramniklal Gosalia was appointed as Director on 27 May 2026.
Appointed
Pradeep Ramniklal Gosalia was appointed as Director.
Appointed
Salma Badrudin Thobhani was appointed as Director.
AGM
Parmax Pharma Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Ceased
Bhakti Rameshbhai Aghera ceased to be Company Secretary.
Charges
A charge with Others amounted to Rs. 8.40 Cr with Charge ID 101092470 was registered on 17 Apr 2025.
Charges
A charge registered on 31 May 2023 via Charge ID 100775935 with Others was fully satisfied on 07 Apr 2025.
Filing
Parmax Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Ahmedabad.
Appointed
Bhakti Rameshbhai Aghera was appointed as Company Secretary.
Charges
A charge with Others of Rs. 6.72 Cr registered on 31 May 2023 with Charge ID 100775935 was modified on 10 Nov 2023.
Charges
A charge registered on 08 Feb 2019 via Charge ID 100240259 with Hdfc Bank Limited was fully satisfied on 16 Oct 2023.
Charges
A charge registered on 16 Oct 2018 via Charge ID 100215130 with Hdfc Bank Limited was fully satisfied on 16 Oct 2023.
Charges
A charge with Others amounted to Rs. 6.72 Cr with Charge ID 100775935 was registered on 31 May 2023.
29 earlier events are in the company report.
News
Frequently asked questions
Parmax Pharma is an active public limited company based in Hadamtala, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 02 November 1994 (32+ years old) and is registered under CIN L24231GJ1994PLC023504.
Parmax Pharma has 5 current directors:
- Umang Alkesh Gosalia - Managing Director
- Ami Shah Rajeshbhai - Director
- Nikhil Sureshchandra Uchat - Director
- Pradeep Ramniklal Gosalia - Director
- Salma Badrudin Thobhani - Director
The latest financial statements of Parmax Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Parmax Pharma is 24AADCP9295L1ZS, registered in Gujarat.
The CIN (Corporate Identification Number) of Parmax Pharma is L24231GJ1994PLC023504. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Parmax Pharma is recorded as a listed company by MCA, but trading in its shares on BSE (540359) has been suspended, so they do not currently trade on a stock exchange.
Parmax Pharma has 2 court cases on record: 2 filed against it.
Parmax Pharma was incorporated on 02 November 1994, making it 32+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Parmax Pharma has 7 deals on record (7 market trades); the latest was in August 2026.
The peers of Parmax Pharma by revenue are Asg Biochem Private Limited, Livmore Life Sciences Private Limited, Surya Remedies Private Limited, Pranami Drugs Private Limited, Aresko Life Sciences Private Limited and 4 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Pradeep Ramniklal Gosalia was appointed as Director on 27 May 2026. Salma Badrudin Thobhani was appointed as Director on 27 May 2026. Bhakti Rameshbhai Aghera ceased to be Company Secretary on 10 Jul 2025. Parmax Pharma has 27 board changes on record in total.
Yes, Parmax Pharma is registered as a small enterprise under Udyam registration (number: UDYAM-GJ-20-0010152).
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages